14. LIFE BELOW WATER

FY2023 EPS Estimates for Aldeyra Therapeutics, Inc Lifted by Oppenheimer (NASDAQ:ALDX) – MarketBeat

Written by Amanda

Aldeyra Therapeutics, Inc (NASDAQ:ALDXGet Rating) – Stock analysts at Oppenheimer boosted their FY2023 EPS estimates for shares of Aldeyra Therapeutics in a note issued to investors on Wednesday, June 8th. Oppenheimer analyst J. Kim now expects that the biotechnology company will earn ($0.94) per share for the year, up from their prior forecast of ($0.97). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($1.37) per share. Oppenheimer also issued estimates for Aldeyra Therapeutics’ FY2025 earnings at $0.56 EPS. Aldeyra Therapeutics (NASDAQ:ALDXGet Rating) last issued its earnings results on Thursday, May 5th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.02. During the same quarter in the prior year, the firm earned ($0.25) earnings per share.

Other research analysts have also recently issued reports about the stock. Citigroup increased their price target on shares of Aldeyra Therapeutics from $21.00 to $26.00 and gave the company a “buy” rating in a report on Thursday. StockNews.com started coverage on shares of Aldeyra Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating on the stock. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Aldeyra Therapeutics in a research report on Wednesday, April 27th. Finally, Berenberg Bank started coverage on shares of Aldeyra Therapeutics in a research report on Tuesday, May 24th. They set a “buy” rating and a $28.00 target price on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Aldeyra Therapeutics has an average rating of “Buy” and an average price target of $19.00.

(Ad)

Learn strategies for how to make money no matter the market direction. Save your seat at our FREE, LIVE online class.

Find out how to navigate volatility and choppy markets.

Aldeyra Therapeutics stock opened at $3.57 on Monday. The stock has a market cap of $208.13 million, a P/E ratio of -3.22 and a beta of 1.64. The company has a quick ratio of 13.60, a current ratio of 13.60 and a debt-to-equity ratio of 0.08. Aldeyra Therapeutics has a twelve month low of $2.36 and a twelve month high of $12.73. The company’s 50-day moving average price is $3.40 and its two-hundred day moving average price is $4.17.

A number of institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at $31,000. Knoll Capital Management LLC raised its stake in shares of Aldeyra Therapeutics by 33.4% during the fourth quarter. Knoll Capital Management LLC now owns 759,405 shares of the biotechnology company’s stock valued at $3,038,000 after acquiring an additional 190,000 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Aldeyra Therapeutics by 40.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 24,298 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 7,002 shares during the last quarter. Geode Capital Management LLC raised its stake in Aldeyra Therapeutics by 0.4% during the third quarter. Geode Capital Management LLC now owns 901,917 shares of the biotechnology company’s stock worth $7,918,000 after buying an additional 3,400 shares during the last quarter. Finally, Kestra Advisory Services LLC raised its stake in Aldeyra Therapeutics by 33.4% during the fourth quarter. Kestra Advisory Services LLC now owns 16,809 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,212 shares during the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Aldeyra Therapeutics (Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Aldeyra Therapeutics right now?

Before you consider Aldeyra Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aldeyra Therapeutics wasn’t on the list.

While Aldeyra Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Source: marketbeat.com

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai